Skip to content

Newly Designed Fully Covered Metal Stent for the Benign Biliary Stricture

Newly Designed Fully Covered Metal Stent for the Benign Biliary Stricture: Prospective Randomized Study

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00945516
Enrollment
60
Registered
2009-07-24
Start date
2009-01-31
Completion date
2010-05-31
Last updated
2010-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bile Duct Disease

Keywords

Metal stent, Bile duct stricture, Stent migration, Feasibility, Safety, Removability

Brief summary

The purpose of this study is to determine the feasibility, easy removability, safety, and migration rate of flared end fully covered self-expanding metal stent (FCSEMS) and anchoring FCSEMS for benign biliary stricture.

Detailed description

Benign biliary strictures (BBS) are usually managed with plastic stents, whereas placement of uncovered metallic stents has been associated with failure related to mucosal hyperplasia. Fully covered self-expanding metal stent(FCSEMS) placement was reported as a useful method for BBS. However, stent migration was a frequent complication of CSEMS placement. Recently, flared end FCSEMS was developed to decrease stent migration, and anchoring CSEMS was newly developed.

Interventions

DEVICEBona stent® (Flared end FCSEMS)

Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.

DEVICEHanarostent® (Anchoring FCSEMS)

Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.

Sponsors

Asan Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patient over 18 years old * Patient with benign bile duct stricture

Exclusion criteria

* No written informed consent * Malignant biliary obstruction * Patients with uncorrectable severe coagulopathy * Patients with severe cardiopulmonary disease precluding sedation

Design outcomes

Primary

MeasureTime frame
Stent migration rateone year

Secondary

MeasureTime frame
Feasibility (Technical success rate and functional success rate)one year
Safety (Procedure related early complications occurred within one month and late complications occurred one month after the procedure)one year
Removabilityone year

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026